| Literature DB >> 29166590 |
Elise Dalmas1, Frank M Lehmann2, Erez Dror3, Stephan Wueest4, Constanze Thienel3, Marcela Borsigova3, Marc Stawiski3, Emmanuel Traunecker5, Fabrizio C Lucchini4, Dianne H Dapito6, Sandra M Kallert5, Bruno Guigas7, Francois Pattou8, Julie Kerr-Conte8, Pierre Maechler9, Jean-Philippe Girard10, Daniel Konrad4, Christian Wolfrum6, Marianne Böni-Schnetzler3, Daniela Finke2, Marc Y Donath3.
Abstract
Pancreatic-islet inflammation contributes to the failure of β cell insulin secretion during obesity and type 2 diabetes. However, little is known about the nature and function of resident immune cells in this context or in homeostasis. Here we show that interleukin (IL)-33 was produced by islet mesenchymal cells and enhanced by a diabetes milieu (glucose, IL-1β, and palmitate). IL-33 promoted β cell function through islet-resident group 2 innate lymphoid cells (ILC2s) that elicited retinoic acid (RA)-producing capacities in macrophages and dendritic cells via the secretion of IL-13 and colony-stimulating factor 2. In turn, local RA signaled to the β cells to increase insulin secretion. This IL-33-ILC2 axis was activated after acute β cell stress but was defective during chronic obesity. Accordingly, IL-33 injections rescued islet function in obese mice. Our findings provide evidence that an immunometabolic crosstalk between islet-derived IL-33, ILC2s, and myeloid cells fosters insulin secretion.Entities:
Keywords: Aldh1a2; ILC2; beta cells; innate lymphoid cells; insulin; interleukin-33; islet
Mesh:
Substances:
Year: 2017 PMID: 29166590 DOI: 10.1016/j.immuni.2017.10.015
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745